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Abstract
Background: Patients with unilateral sciatica have heightened responses to intradermal capsaicin compared to pain-free
volunteers. No studies have investigated whether this pain model can screen for novel anti-neuropathic agents in patients
with pre-existing neuropathic pain syndromes.
Aim: This study compared the effects of pregabalin (300 mg) and the tetracycline antibiotic and glial attenuator
minocycline (400 mg) on capsaicin-induced spontaneous pain, flare, allodynia and hyperalgesia in patients with unilateral
sciatica on both their affected and unaffected leg.
Methods/Results: Eighteen patients with unilateral sciatica completed this randomised, double-blind, placebo-controlled,
three-way cross-over study. Participants received a 10 mg dose of capsaicin into the middle section of their calf on both their
affected and unaffected leg, separated by an interval of 75 min. Capsaicin-induced spontaneous pain, flare, allodynia and
hyperalgesia were recorded pre-injection and at 5, 20, 40, 60 and 90 min post-injection. Minocycline tended to reduce pre-
capsaicin injection values of hyperalgesia in the affected leg by 28% (95% CI 0% to 56%). The area under the effect time
curves for capsaicin-induced spontaneous pain, flare, allodynia and hyperalgesia were not affected by either treatment
compared to placebo. Significant limb differences were observed for flare (AUC) (238% in affected leg, 95% CI for difference
219% to 252%). Both hand dominance and sex were significant covariates of response to capsaicin.
Conclusions: It cannot be concluded that minocycline is unsuitable for further evaluation as an anti-neuropathic pain drug
as pregabalin, our positive control, failed to reduce capsaicin-induced neuropathic pain. However, the anti-hyperalgesic
effect of minocycline observed pre-capsaicin injection is promising pilot information to support ongoing research into glial-
mediated treatments for neuropathic pain. The differences in flare response between limbs may represent a useful
biomarker to further investigate neuropathic pain. Inclusion of a positive control is imperative for the assessment of novel
therapies for neuropathic pain.
Citation: Sumracki NM, Hutchinson MR, Gentgall M, Briggs N, Williams DB, et al. (2012) The Effects of Pregabalin and the Glial Attenuator Minocycline on the
Response to Intradermal Capsaicin in Patients with Unilateral Sciatica. PLoS ONE 7(6): e38525. doi:10.1371/journal.pone.0038525
Editor: Kazutaka Ikeda, Tokyo Metropolitan Institute of Medical Science, Japan
Received January 15, 2012; Accepted May 5, 2012; Published June 7, 2012
Copyright:  2012 Sumracki et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: nicole.sumracki@adelaide.edu.au
Introduction
The management of chronic neuropathic pain is a major
unmet medical need [1] with few new classes of drugs reaching
clinical practice and none of which are disease modifying.
Recently, the potential role of glial activation in initiating and
promoting the development of chronic neuropathic pain has
been convincingly demonstrated in animals [2,3,4]. However,
there is no access to the central nervous system and no
validated imaging tools for assessing glial activation in humans.
Hence, the determination of the role of glial activation in
humans is difficult, with functional assessment being the only
current feasible method that can be used. Although there have
been small trials of potential glial inhibitors in clinical trials
[5,6,7,8,9,10,11,12,13,14,15], no adequately powered trial has
been reported. Trials in chronic pain are notoriously difficult in
which to elicit a drug signal due to large and variable placebo
response, regression to the mean and participant withdrawal
[16]. An alternative method for seeking such a signal is to
perform a carefully standardised neuropathic-like stimulus (pain
model) in patients with chronic pain. It has been suggested that
a chronic state of glial activation may exist in patients with
neuropathic pain; hence novel disease-modifying therapies need
to be investigated in the diseased patient (i.e. patients with
neuropathic pain) as investigation of such disease modifying
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negative response due to the likely quiescent state of glia in
healthy volunteers.
We report such a trial where intradermal capsaicin, intended to
produce a transiently heightened neuropathic-like state, has been
applied to the limbs of patients with unilateral sciatica, a condition
of mixed basis [17] but with some neuropathic element in many
patients. In the current study however, we attempted to determine
whether the glial inhibitor and tetracycline antibiotic, minocycline,
could reduce the response to intradermal capsaicin. Previously,
numerous rodent studies have demonstrated that minocycline
attenuates glial activation and possesses both neuroprotective and
anti-inflammatory properties independent of its antibiotic activity
[18]. Furthermore, the use of minocycline as a potential glial
inhibitor in humans is justified due to its well known safety profile
[19]; its ability to readily penetrate the blood-brain brain barrier
[20], thereby gaining access to the central nervous system; and its
ability to safely reach therapeutic levels in humans. However,
minocycline only appears to be effective in reducing neuropathic
pain in rodents if administered pre-emptively [21] and hence
might not reduce pre-existing neuropathic pain, but might
attenuate the response to a new neuropathic-like stimulus. We
have previously demonstrated that intradermal capsaicin produces
a transiently heightened neuropathic-like state in both healthy
volunteers [22] and in patients with unilateral sciatica [23] with
a dose-response relationship. Hence intradermal capsaicin was
selected to safely provide such a stimulus. Given the difficulty in
interpreting a negative response, we have attempted to incorporate
a positive control for the response to capsaicin. We selected
pregabalin as the positive control due to its modest, yet non-
statistically significant reduction of capsaicin-induced secondary
hyperalgesia observed by Wang and colleagues [24] in healthy
male volunteers.
We hypothesised that pregabalin would reduce capsaicin-
induced spontaneous pain, flare, allodynia and hyperalgesia as
evidence of general anti-neuropathic effects and that minocycline
would also attenuate the response to capsaicin by attenuation of
the glial contributions to the new neuropathic-like pain stimulus
that the capsaicin challenge produces.
Materials and Methods
Participant Selection
Sciatica was diagnosed on clinical grounds by the presence of
pain in the L5/S1 dermatomal distribution accompanied by
dysaethesia of a shocking or burning quality of pain. Participants
were to have negligible pain symptoms in their contralateral leg.
The first and last patients were randomised on the 29
th of June
2009 and the 27
th of July 2009 respectively.
Inclusion and Exclusion Criteria
Key inclusion criteria were: being between 18 and 65 years old
inclusive; having both lower limbs present; and having suffered
from unilateral sciatica for a minimum of 3 months, with this being
their dominant pain problem. Additionally, women of childbear-
ing potential using hormonal contraception were only eligible if
they agreed to additional barrier contraception until their first
normal period after the study, due to contraindications of
minocycline and must have had a negative pregnancy test prior
to each testing session. Exclusion criteria included: known
intolerance to capsaicin, pregabalin or minocycline; being
pregnant or breastfeeding; scarring or tattoos on either leg at the
planned site of injection; deep skin pigmentation which would
have precluded the flare assessment; and recent use of opioids (e.g.
morphine use within 1 week) or pain modifying drugs (e.g. tricyclic
antidpressants, gabapentin or pregabalin use within 1 month).
Participants on paracetamol or non-steroidal anti-inflammatory
drugs (NSAIDs) were required to withhold medication for 24 h or
5 half lives of the medication, whichever was longer, prior to each
study day to exclude any effect on the capsaicin response.
Participants were also excluded if their creatinine clearance as
estimated by Cockcroft-Gault was less than 60 mL/min.
Ethics
Ethics approval was obtained from the Royal Adelaide Hospital
Research Ethics Committee. Signed consent was obtained from
each participant prior to enrolment into the study and participants
were financially compensated for their time and inconvenience.
Capsaicin Preparation
Capsaicin in 38% hydroxypropyl-b-Cyclodextrin (b-CD) was
prepared and dispensed as described previously [22]. A 10 mg dose
was selected based on previous work from our laboratory [23]. For
each injection, 10 mL of solution was drawn into a 0.3 mL sterile
insulin syringe (BD Ultra-Fine II) by the Royal Adelaide Hospital
Department of Pharmacy.
Familiarisation
As part of the screening session, participants were familiarised to
the four outcome measures of spontaneous pain, area of flare,
allodynia and hyperalgesia, described below, in response to a single
intradermal capsaicin injection of 10 mgi n1 0mL 38% hydro-
xypropyl-b-CD. All outcome measures were tested before and
5 min post-injection.
Assessment Procedures
This randomised, double-blinded, placebo-controlled, double-
dummy, three-way cross over study was conducted over 365h
sessions, with a one week washout in between each session. The
three study treatments were single oral doses of minocycline,
pregabalin and placebo. Order of treatment allocation was
randomised using a Latin square design to control for any
potential carry-over effect between study days. On each dosing
occasion, participants received either an oral dose of (1)
minocycline (400 mg) at 22 h and placebo pregabalin at 21h ;
or (2) placebo minocycline at 22 h and pregabalin (300 mg) at
21 h; or (3) placebo minocycline at 22 h and placebo pregabalin
at 21 h before the first intradermal capsaicin injection, according
to a double-dummy design. The time points for study treatment
administration were chosen based on the pharmacokinetic profiles
of both minocycline and pregabalin, to ensure that both capsaicin
injections would be administered as equally as possible to either
side of minocycline or pregabalin’s plasma peak concentration. An
equal number of capsules of the active and placebo treatments
were administered orally to each participant to avoid potential un-
blinding. Therefore, minocycline was administered as 46100 mg
capsules; pregabalin as 4675 mg capsules and placebo as
46starch capsules. Due to dissimilarities between the capsules,
a member of staff (who were otherwise not involved in any of the
assessments) administered the different treatments and the
participants were blindfolded throughout treatment administration
to avoid treatment allocation un-blinding. Throughout the
assessments, participants lay prone on a bed, and the skin
temperature of the test site was fixed at 34–36uC, using a 250 W
infrared heat lamp positioned approximately 50 cm from the back
of the calf, as this has been previously shown to reduce the
variability of the intradermal capsaicin pain model in the volar
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monitored using a thermode on the adjacent skin. Participants
received two injections of intradermal capsaicin per dosing
occasion, with each injection separated by an interval of 75 min.
The injections were administered to the middle section of the calf
on both their affected and unaffected leg, with the order of
injections according to a random code. Spontaneous pain, area of
flare, allodynia and hyperalgesia (in that order) were measured
prior to and at 5, 20, 40, 60 and 90 min post injection. All
assessments were measured and recorded by the same assessor to
maintain consistency between measurements. Collectively, all four
assessments took about 3 min to complete.
1. Spontaneous pain. Capsaicin-induced spontaneous pain
was assessed using a 100 mm visual analogue scale (VAS).
Participants were required to mark the severity of their pain
from a score of 0, indicating ‘no pain’ to 100, signifying ‘the
worst pain imaginable’. The length (mm) was recorded with
a ruler.
2. Flare. Capsaicin-induced area of flare (cm
2) was assessed by
tracing the visually identified area of reddened skin directly
onto an overlaying transparent acetate sheet, using a soft-
tipped pen [23]. The area was then calculated using digital
planimetry.
3. Allodynia. The average radius (cm) of capsaicin-induced
allodynia was assessed using a foam paint brush (Foam brush
2*ROYMAC, Australia), gently stroked across the skin along 8
compass directions as previously described [23]. The average
sum of each radii between the marked dot and the injection site
was later determined. This has been found to be more
appropriate than measuring an area of allodynia or hyper-
algesia, as not all assessments result in eight points of response
[23].
4. Hyperalgesia. The average radius (cm) of capsaicin-induced
hyperalgesia was assessed using a calibrated von Frey hair,
a plastic rod that bends at a defined pressure (SENSELab
monofilaments, Somedic, Horby, Sweden). The von Frey hair
was applied along 8 compass directions as described above for
allodynia. Participants were instructed to say ‘yes’ if they
noticed an ‘increase in pain’ or a ‘change in sensation’, and the
average of these points was then recorded and measured as
described for allodynia. The von Frey hair selected for each
participant was the highest von Frey hair that produced
discomfort but no pain prior to intradermal capsaicin at the
screening session. This hair was selected by applying each von
Frey hair (from lowest to highest) three times to the middle
section of the calf on the participants affected leg until the
participant reported a painful response. The von Frey hair
below the one that elicited a painful response was then selected,
and was used for the entire duration of the study for that
particular participant.
Statistics
A power calculation was performed based on a previous study
investigating intradermal capsaicin and pregabalin in healthy
volunteers [24] to detect a 25% difference between treatments
with an alpha level of 0.05. This requried between 11 and 18
participants to ensure 80% power in detecting a change for a two-
tailed test. Given the uncertainty of the effect size of minocycline
and pregabalin in patients with unilateral sciatica, and the
exploratory nature of this study, a sample size of 18 was selected.
The primary endpoint was to compare the effects of minocycline
and pregabalin with placebo on capsaicin induced spontaneous
pain (mm), area of flare (cm
2), allodynia (average radius, cm) and
hyperalgesia (average radius, cm) in patients with unilateral
sciatica, on both their affected and unaffected leg. A linear mixed
effects model was fitted to each of the primary endpoints predicted
by order of injection (affected or unaffected leg); order of treatment
and time, and their interactions. The model assesses the
interaction between variables and subsequently is used to estimate
point estimates and the 95% confidence intervals for each variable
and for differences between variables. Main effects of sex; hand
dominance and affected leg status were included as covariates in
this model. The effect of intradermal capsaicin on spontaneous
pain, flare, allodynia and hyperaglesia (placebo data only) was
analysed using a one-way repeated measures (RM) ANOVA.
Holm’s Stepdown Bonferroni adjustment was performed to adjust
for multiple comparisons. Statistical analysis was performed using
the SAS 9.1 Program, SAS Institute Inc., Cary, NC, USA and
Prism software version 5 (GraphPad Software, San Diego, CA,
USA). A P value of less than 0.05 was required for statistical
significance. All P values are expressed as unadjusted values unless
otherwise stated.
Results
Subjects
18 participants with unilateral sciatica (13 males and 5 females,
mean age 49.4611.4 years) completed this study. An additional
participant withdrew after the first study day, due to unknown
reasons. Unblinding revealed that this participant received placebo
treatment. Their placebo data were included in the analyses. The
duration of disease ranged from 10 months to 24 years, with
a mean of 7.7 years (95% CI : 3.9 to 11.5 years). All participants
were Caucasian. Demographics and concomitant medications are
listed in Table 1.
Tolerability and Safety
Capsaicin doses were well tolerated by all participants, with no
adverse effects reported or observed, other than the expected local
responses. Minocycline doses were well tolerated by most
participants, with only two participants experiencing adverse
effects which included dizziness; difficulty focussing and headache.
Fourteen participants experienced adverse effects such as dizzi-
ness, nausea and tiredness following pregabalin treatment. One
participant reported tiredness following placebo. Most adverse
effects, such as dizziness and nausea, were not reported or
observed until the end of the study day, when participants sat
Table 1. Patient Demographics.
Sex (M/F) 13/5
Age (years, mean 6 SD) 49.4611.4
Race (%) Caucasian 100
Duration of Disease
(years 6 SD)
7.767.7
Concominant Medications
(%)
Paracetamol 48
Paracetamol + Codeine 5
NSAIDs 5
NSAIDs + Codeine 21
Diazepam 16
NSAIDs: Nonsteroidal anti-inflammatory drugs.
doi:10.1371/journal.pone.0038525.t001
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assessments.
VAS Score
Effect-time profiles are shown in Figure 1 panels A (affected
leg) and B (unaffected leg). Baseline values of pain in the
placebo group were 13 mm (95% CI 1 mm to 25 mm) in the
affected leg, indicating a low baseline level of symptoms, and
4 mm (95% CI 20.1 mm to 9 mm) in the unaffected,
confirming the largely unilateral nature of symptoms. The
effect-time profiles for the VAS scores following capsaicin in
both the affected leg and unaffected leg were similar, with the
peak response occurring at t=5 min, followed by a gradual
decline over time. The AUC (see table 2 for all AUC values) of
VAS scores was 28% (95% CI 8% to 43%) lower in the
unaffected leg compared to the affected leg. However, once
adjusting for multiple comparisons, statistical significance was
lost (p.0.05). Neither pregabalin nor minocycline reduced the
AUC of VAS scores in either the affected or unaffected leg
(p.0.05). A one-way RM ANOVA demonstrated that the
10 mg dose of intradermal capsaicin used caused a significant
increase in pain from baseline at t=5 min (23 mm increase,
95% CI for increase 13 mm to 34 mm) in the affected leg [F (5,
18)=16.61, p,0.0001] and at t=5 min (25 mm increase, 95%
CI for increase 17 mm to 34 mm) and t=20 min (11 mm
increase, 95% CI for increase 2 mm to 19 mm) in the
unaffected leg [F (5, 18)=21.23, p,0.0001] when placebo
was administered, demonstrating intradermal capsaicin’s ability
to induce a level of spontaneous pain that is generally
considered at the lower end of clinically significant pain
(,40 mm).
Area of Flare
Effect time profiles are shown in Figure 1, panels C (affected
leg) and D (unaffected leg). Baseline flare values were zero in
the affected and unaffected leg, as expected. The time profiles
for area of flare differed in the affected and unaffected leg. In
the affected leg, the peak response occurred at t=20 min for all
treatments, followed by a decline over the 90 min session. In
the unaffected leg, the response appeared to increase and stay
steady over the 90 min session, with the peak response at
t=40 min for placebo and pregabalin, and at t=60 min for
minocycline. Neither pregabalin nor minocycline had an effect
on the areas of flare in either the affected or the unaffected leg
(p.0.05). The AUC of flare was significantly lower in the
affected leg by 38% (95% CI 19% to 52%, p=0.024) (adjusted
p value) compared to the unaffected leg. A one-way RM
ANOVA demonstrated that the 10 mg dose of intradermal
capsaicin caused a significant increase in mean (95% CI) flare
from baseline at t=5 min : 26.7 cm
2 (14.7–38.5 cm
2),
t=20 min : 29.8 cm
2 (17.9–41.7 cm
2), t=40 min : 21.5 cm
2
(9.6–33.4 cm
2), t=60 min : 20.0 cm
2 (8.1–31.6 cm
2) and
t=90 min : 19.7 cm
2 (7.8–31.6 cm
2) in the affected leg [F (5,
18)=10.59, p,0.0001] and at t=5 min : 42.6 cm
2 (12.8–
72.4 cm
2), t=20 min : 56.7 cm
2 (26.9–86.5 cm
2), t=40 min :
63.9 cm
2 (34.1–93.6 cm
2), t=60 min : 53.9 cm
2 (24.1–83.7 cm
2)
and t=90 min : 54.6 cm
2 (24.9–83.4 cm
2) in the unaffected leg
[F (5, 18)=8.41, p,0.0001] when placebo was administered.
Significant differences were observed between the areas of flare
in the affected and unaffected leg at t=40 min (p=0.0078),
t=60 min (p=0.038) and t=90 min (p=0.0068) for placebo,
and at t=90 min for both minocycline (p=0.0059) and
pregabalin (p=0.021), demonstrating an increasing area of flare
in the unaffected leg over the 90 min session.
Allodynia
Effect time profiles are shown in Figure 1 panels E (affected leg)
and F (unaffected leg). Positive allodynia baseline values were
observed in both the affected (average radius 0.6 cm, 95% CI
0.2 cm to 1.1 cm) and unaffected leg (average radius 0.2 cm, 95%
CI 20.08 cm to 0.4 cm) in the placebo group. Mean allodynia
responses appeared to resolve to pre-capsaicin injection values at
a faster rate in the affected leg compared to the unaffected. There
was no significant difference between the means over the 90 min
session between the affected and the unaffected leg. Neither
pregabalin nor minocycline reduced the AUC of allodynia in
either the affected or the unaffected leg (p.0.05). A one-way RM
ANOVA demonstrated that the 10 mg dose of intradermal
capsaicin used caused a significant, although very small, increase
in allodynia from baseline at t=5 (0.5 cm increase, 95% CI for
increase 0 cm to 1.1 cm) in the affected leg [F (5, 18)=3.31,
p=0.0087] and at t=5 min (0.5 cm increase, 95% CI for increase
0 cm to 0.9 cm) and t=20 min (0.5 cm increase, 95% CI for
increase 0 cm to 0.9 cm) in the unaffected leg [F (5, 18)=2.27,
p=0.054] when placebo was administered.
Hyperalgesia
Effect time profiles are shown in Figure 1 panels G (affected leg)
and H (unaffected leg). Positive hyperalgesia baseline values were
observed in both the affected and unaffected leg, with slightly
higher values in the affected leg. Minocycline reduced pre-
capsaicin injection values of hyperalgesia (average radius, cm) in
the affected leg by approximately 28% compared to placebo, with
borderline significance (95% CI 0% to 56%, p=0.053). However,
once adjusting for multiple comparisons, statistical significance was
lost (p=0.91). There was no significant difference between the
means over the 90 min session between the affected and un-
affected leg. Neither pregabalin nor minocycline reduced the AUC
of hyperalgesia in either the affected or the unaffected leg
(p.0.05). A one-way RM ANOVA demonstrated that the 10 mg
dose of intradermal capsaicin used was insufficient to produce
increased hyperalgesia responses from baseline in the affected leg
when placebo was administered [F (5, 18)=1.12, p=0.31].
However, the 10 mg dose of intradermal capsaicin used caused
a significant, although very small, increase in hyperalgesia from
baseline in the unaffected leg at t=20 min (0.9 cm increase, 95%
CI for increase 0.1 cm to 1.8 cm), t=40 min (1.3 cm increase,
95% CI for increase 0.4 cm to 2.1 cm), t=60 min (1.3 cm
increase, 95% CI for increase 0.4 cm to 2.1 cm) and t=90 min
(1.3 cm increase, 95% CI for increase 0.4 cm to 2.1 cm) when
placebo was administered [F (5, 18)=5.01, p=0.0004].
Discussion
The scarcity of experimental pain studies in patients with
chronic pain makes the interpretation of results generated by
studies investigating the efficacy of analgesics in pain-free
participants difficult in patients with chronic pain, as it is unknown
whether the mechanistic processing of experimental pain differs
between patients with chronic pain and pain-free participants. If
indeed the mechanistic processing of experimental pain differs
between patients with chronic pain and pain-free participants, the
response to challenge agents, such as capsaicin, and the response
to both positive and negative controls will not necessarily be
similar in patients with chronic pain and pain-free participants.
Therefore, further investigation of experimental pain is required in
patients with chronic pain. Although we report a negative result,
these findings are important for others working in this research
area when considering experimental design factors.
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either the positive control pregabalin or the experimental drug
minocycline. The study design was based on that of Wang et al.
[24], who showed a non-statistically significant reduction in
hyperalgesia to 100 mg of capsaicin in healthy volunteers following
pregabalin. In our previous study (Aykanat et al., [23]), comparing
the responses to intradermal capsaicin between healthy volunteers
and patients with unilateral sciatica, we saw a considerably
enhanced response to all variables in the patients and hence used
a lower dose of capsaicin (10 mg) than that used in the study of
Wang et al., [24], as we were concerned that higher doses might
not be tolerated. Following 10 mg of intradermal capsaicin, we
observed increased responses to the variables spontaneous pain,
flare and allodynia in both the affected and unaffected limb and
hyperalgesia in the unaffected limb compared to pre-capsaicin
injection responses, whereas hyperalgesia in the affected limb
remained unaltered post-capsaicin injection compared to pre-
capsaicin injection. Given that there was no increase in
hyperalgesia in the affected limb, and only small increases in
hyperalgesia in the unaffected limb following capsaicin, it is not
surprising that we saw no effect of the positive control, as
a reduction in post-capsaicin hyperalgesia was the primary
outcome. Given the capsaicin was very well tolerated in both this
study and in our previous study [23], and that it is essential to
produce a robust hyperalgesia profile, we propose to use a higher
dose of capsaicin in future studies.
Of particular interest is the difference observed in flare
responses between the affected and unaffected limb of patients
with unilateral sciatica. Similar to Aykanat et al., [23], flare
responses were lower in the affected leg compared to the
unaffected leg of unilateral sciatica patients. Lower capsaicin-
induced flare responses have also been observed in the affected
regions of lower lumbar pain [26] and post-herpetic neuralgia
(PHN) patients [26,27,28] when compared to pain patients flare
responses in an unaffected body site. Morris et al., [27] demon-
strated that PHN patients who experience allodynia have lower
capsaicin-induced flare responses compared to PHN patients who
do not experience allodynia and healthy volunteers. However, no
correlation between the amount of allodynia experienced and
capsaicin-induced flare was demonstrated in this study. Flare has
previously been attributed to an axon reflex of C-fibres.
Consequently, neuronal loss may result in reduced flare responses.
Although the participants in this study did not present clinical
evidence of sensory loss, it has previously been demonstrated that
patients with type 2 diabetes without clinical signs of neuropathy
had significantly reduced flare responses compared to healthy
volunteers when flare was induced by heating the skin to 44uC
[29]. Accordingly, our results support the abovementioned
previous findings of reduced flare responses in the painfully
affected body region; and give further support to a neuropathic
component in sciatica. Alternatively the reduced flare observed in
the affected leg may be due to increased inhibitory control. If true,
the capsaicin-induced flare response may represent a biomarker of
descending inhibitory control.
Only three studies have previously investigated the response to
intradermal capsaicin in patients with pain; with these being in
vulvodynia-afflicted women [30], patients with rheumatoid
arthritis [31] and patients with unilateral sciatica [23]. Shenker
et al., [31] investigated bilateral capsaicin-induced hyperalgesia
and allodynia in response to intradermal capsaicin administered
unilaterally, thus did not compare capsaicin-induced responses
between patients with rheumatoid arthritis and pain-free controls
in the injected capsaicin limb [31]. However, the studies in
vulvodynia-afflicted women [30] and patients with unilateral
sciatica [23] demonstrated significantly heightened capsaicin-
induced responses in patients with pain compared to pain-free
controls, supporting the feasibility of investigating this neuro-
pathic pain model in patients with neuropathic pain. To our
Figure 1. Capsaicin-induced spontaneous pain, flare, hyperalgesia and allodynia. Time course of capsaicin-induced spontaneous pain,
flare, allodynia and hyperalgesia responses following placebo (N), single oral dose minocycline (400 mg &) and single oral dose pregabalin (300 mg
m) in patients with unilateral sciatica in their affected (A, C, E, G) and unaffected (B, D, F, H) leg. Data presented as mean 6 SEM.
doi:10.1371/journal.pone.0038525.g001
Table 2. AUC of capsaicin-induced spontaneous pain, flare, allodynia and hyperalgesia in patients with unilateral sciatica in their
affected and unaffected leg.
Outcome Measured Treatment Mean AUC (95% CI)
Affected Leg Unaffected Leg
Spontaneous pain Placebo 656.5 (386.9, 1114.1) 489.7 (288.6, 831.0)
Pregabalin 752.5 (422.9, 1338.8) 485.6 (272.9, 864.0)
Minocycline 750.8 (420.3, 1341.3) 592.0 (331.3, 1057.4)
Flare Placebo 1475.2 (985.0, 2210.0) 3176.2 (2120.6, 4757.4)
Pregabalin 1936.3 (1244.2, 3013.2) 2286.7 (1469.4, 3558.6)
Minocycline 1673.6 (1049.0, 2671.0) 2766.1 (1733.1, 4414.7)
Allodynia Placebo 28.9 (12.3, 68.1) 17.2 (7.4, 40.7)
Pregabalin 23.9 (11.9, 48.0) 20.5 (10.2, 41.1)
Minocycline 15.5 (7.0, 34.3) 16.2 (7.3, 35.9)
Hyperalgesia Placebo 373.2 (282.3, 464.1) 363.0 (272.0, 453.9)
Pregabalin 303.5 (209.8, 397.1) 306.9 (213.2, 400.5)
Minocycline 337.3 (241.4, 433.1) 354.0 (258.2, 449.8)
AUC: Area under the curve.
doi:10.1371/journal.pone.0038525.t002
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whether the intradermal capsaicin pain model can screen for
novel anti-neuropathic agents in patients with pre-existing
neuropathic pain.
Although not significant once adjusting the P-value, the 28%
(95% CI 0% to 56%) reduction of hyperalgesia in the affected leg
prior to intradermal capsaicin by single oral dose minocycline is
a novel finding that glial attenuation may be anti-hyperalgesic in
humans. Similar results have been demonstrated in animal studies,
where minocycline administration post-spinal cord injury for five
consecutive days significantly increased mechanical nociceptive
thresholds in male Sprague-Dawley rats compared to vehicle
treated rats [32]. However, the absence of pre-drug administration
assessments makes interpretation of this reduced pre-capsaicin
baseline following minocycline difficult.
Pregabalin did not reduce capsaicin-induced spontaneous pain.
Although there was a clear capsaicin effect, the main peak effect
was below the 40 mm value generally accepted as the minimum
for clinically relevant pain [33]. This is further argument to use
a higher dose of capsaicin in future studies in order to produce
clinically relevant pain, which may be attenuated by the
experimental drug. The use of pregabalin as our positive control
was warranted, compared to an opioid analgesic, as pregabalin is
amongst the recommended first-line treatments for neuropathic
pain, as recommended by the Neuropathic Pain Special Interest
Group of the International Association for the Study of Pain [34],
the Canadian Pain Society [35] and the European Federation of
Neurological Studies [36]; whereas opioids are generally consid-
ered as a second-line or even third-line treatment for neuropathic
pain. Consequently, we wished to incorporate a recommended
first-line treatment for neuropathic pain as our positive control.
Pregabalin, a licenced treatment for neuropathic pain, was
incorporated into this study as a positive control. As oral
pregabalin failed to significantly reduce capsaicin-induced neuro-
pathic pain in patients with unilateral sciatica, it cannot be
concluded that minocycline is unsuitable for further evaluation as
an anti-neuropathic pain drug. Therefore, the anti-hyperalgesic
effect observed following single oral dose administration of
minocycline is promising pilot information to support ongoing
research into glial mediated treatments for neuropathic pain. The
findings from this study demonstrate the importance of in-
corporating a positive control when assessing the efficacy of novel
therapies, especially when the effect size of the experimental
stimulus has not been validated in the patient population being
tested. Therefore, future studies utilising the capsaicin-induced
neuropathic pain model in a chronic pain patient population
should ensure that the capsaicin dose selected is an adequate dose
to produce a reliable area of secondary hyperalgesia and allodynia,
whilst maintaining a stimulus intensity that can be tolerated
satisfactorily. Additionally, capsaicin-induced flare responses in
chronic pain patients may provide a simple, objective biomarker to
further investigate neuropathic pain.
Limitations
The key limitation of this study is the unexpectedly low
hyperalgesia produced by capsaicin. This made the detection of
a drug-induced reduction, whether to the positive control or
experimental drug, difficult. Further studies should use a higher
dose of capsaicin.
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